Literature DB >> 29276249

Response to Letter to the Editor on "Enzyme Replacement or Substrate Reduction? A Review of Gaucher Disease Treatment Options".

Alison Van Rossum1, Megan Holsopple2.   

Abstract

Year:  2017        PMID： 29276249      PMCID： PMC5735762          DOI： 10.1177/0018578717737135

Source DB:  PubMed          Journal:  Hosp Pharm        ISSN： 0018-5787


× No keyword cloud information.
  6 in total

1.  Effect of oral eliglustat on splenomegaly in patients with Gaucher disease type 1: the ENGAGE randomized clinical trial.

Authors:  Pramod K Mistry; Elena Lukina; Hadhami Ben Turkia; Dominick Amato; Hagit Baris; Majed Dasouki; Marwan Ghosn; Atul Mehta; Seymour Packman; Gregory Pastores; Milan Petakov; Sarit Assouline; Manisha Balwani; Sumita Danda; Evgueniy Hadjiev; Andres Ortega; Suma Shankar; Maria Helena Solano; Leorah Ross; Jennifer Angell; M Judith Peterschmitt
Journal:  JAMA       Date:  2015-02-17       Impact factor: 56.272

2.  Outcome of pregnancies in women receiving velaglucerase alfa for Gaucher disease.

Authors:  Deborah Elstein; Derralynn Hughes; Ozlem Goker-Alpan; Miriam Stivel; Hagit N Baris; Ian J Cohen; Sorina Granovsky-Grisaru; Arnon Samueloff; Atul Mehta; Ari Zimran
Journal:  J Obstet Gynaecol Res       Date:  2014-02-26       Impact factor: 1.730

3.  Pivotal trial with plant cell-expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease.

Authors:  Ari Zimran; Einat Brill-Almon; Raul Chertkoff; Milan Petakov; Francisco Blanco-Favela; Eduardo Terreros Muñoz; Sergio E Solorio-Meza; Dominick Amato; Gloria Duran; Fiorina Giona; Rene Heitner; Hanna Rosenbaum; Pilar Giraldo; Atul Mehta; Glen Park; Mici Phillips; Deborah Elstein; Gheona Altarescu; Mali Szleifer; Sharon Hashmueli; David Aviezer
Journal:  Blood       Date:  2011-09-06       Impact factor: 22.113

4.  Changes in the atherogenic profile of patients with type 1 Gaucher disease after miglustat therapy.

Authors:  J Puzo; P Alfonso; P Irun; J Gervas; M Pocovi; P Giraldo
Journal:  Atherosclerosis       Date:  2009-10-17       Impact factor: 5.162

5.  Development of anti-velaglucerase alfa antibodies in clinical trial-treated patients with Gaucher disease.

Authors:  Gregory M Pastores; Hadhami Ben Turkia; Derlis E Gonzalez; Hiroyuki Ida; Azza A G Tantawy; Yulin Qin; Yongchang Qiu; Quinn Dinh; Ari Zimran
Journal:  Blood Cells Mol Dis       Date:  2016-03-05       Impact factor: 3.039

6.  Eliglustat maintains long-term clinical stability in patients with Gaucher disease type 1 stabilized on enzyme therapy.

Authors:  Timothy M Cox; Guillermo Drelichman; Renata Cravo; Manisha Balwani; Thomas Andrew Burrow; Ana Maria Martins; Elena Lukina; Barry Rosenbloom; Ozlem Goker-Alpan; Nora Watman; Amal El-Beshlawy; Priya S Kishnani; Maria Lucia Pedroso; Sebastiaan J M Gaemers; Regina Tayag; M Judith Peterschmitt
Journal:  Blood       Date:  2017-02-06       Impact factor: 22.113
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.